Stellar Ocean Medical Secures Nearly RMB 100 Million Series A Financing Led by Legend Capital

VCBeat has learned at the earliest opportunity that,Shenzhen MacroLux Medical Technology Co., Ltd. (hereinafter referred to as “MacroLux”) has recently completed a Series A financing round of nearly RMB 100 million, led by Legend Capital and participated in by Daotong Investment.

MacroLux Medical was established in October 2020, with its headquarters located in Guangming, Shenzhen. It is a medical technology company dedicated to innovative solutions for endoscopic interventional diagnosis and treatment. The founding team hails from leading domestic medical device enterprises, boasting over a decade of experience in product research and development, global marketing, and production management of endoscopes and minimally invasive surgical instruments. Committed to relentless innovation, MacroLux Medical aims to provide comprehensive endoscopic interventional diagnostic and therapeutic solutions covering urology, respiratory, and gastroenterology departments worldwide, enabling earlier disease detection and improved patient care.

Endoscopic diagnosis and treatment are widely used in gastroenterology, urology, pulmonology, otolaryngology, general surgery, gynecology, and other specialties. This approach primarily utilizes flexible endoscopes and associated instruments to diagnose and treat diseases via natural body orifices. Traditional reusable flexible endoscopes pose challenges such as cross-infection risks, high acquisition costs, and low operational efficiency. In response to these needs, single-use electronic endoscopes have emerged, gradually replacing reusable flexible endoscopes in certain departments and achieving rapid growth in market penetration.

Regarding this financing,Zhang Weiqiang, General Manager of MacroLuxStatement: We extend our gratitude to Legend Capital and Daotong Investment for their trust in MacroLux. The single-use electronic endoscope market is an emerging sector experiencing rapid growth. In recent years, MacroLux has focused on product development and technological innovation in single-use endoscopes, establishing strong competitive advantages across multiple dimensions. Leveraging our team’s over a decade of industry experience, we will rapidly deploy solutions globally that better meet customer needs.

Zhou Quan, Managing Director at Legend CapitalStatement: As a key direction for the minimally invasive trend in healthcare, endoscopic diagnosis and treatment has long been a sector of strategic focus for Legend Capital. In recent years, we have observed that single-use endoscopes have addressed the pain points of traditional diagnostic and therapeutic devices across multiple application scenarios and are now gaining rapid market penetration. The functional teams at MacroLux boast extensive experience and years of seamless collaboration, possessing comprehensive commercialization expertise that has driven impressive performance from inception to scale. We are honored to partner with the team and look forward to supporting the company in accelerating clinical adoption through its innovative product portfolio, ultimately benefiting patients worldwide.

Lin Zhencheng, Managing Director at DaoTong InvestmentDaoTong is highly optimistic about the growth potential of the disposable electronic endoscopy market. This technology effectively addresses key pain points associated with traditional reusable endoscopes, such as cross-infection risks and high acquisition costs. Currently, it has been adopted across multiple clinical departments, with its penetration rate rising rapidly. In the future, it is expected to further replace traditional reusable endoscopes in a broader range of scenarios. More importantly, MacroLux boasts an excellent team with a global perspective and extensive expertise in R&D, marketing, and supply chain management. We are delighted to have the opportunity to support this outstanding team as they grow, enabling deeper exploration in this fast-evolving sector and better meeting clinical needs.

Legend Capital, established in April 2001, is a fund management company under Legend Holdings that specializes in early-stage venture capital and growth-stage private equity investments. Over the past two decades, Legend Capital has adhered to international standards, creating best practices in fund operations and management. Through its proactive value-added service system, it fosters innovative corporate growth, consistently delivering strong investment returns across multiple sectors while driving industrial advancement and social development in China. With the vision of “becoming an investment firm with global influence,” Legend Capital upholds the core value of “Wealth with Integrity” and actively fulfills its social responsibilities.

Legend Capital has long focused on investments in the medical device and diagnostics sectors, having invested in a series of leading companies across various niche segments within these fields.

Daotong Investment focuses on early-stage investments in the healthcare industry, with a particular emphasis on innovative medical technologies. It has served as an early investor in numerous pioneering technology projects in China. The core team at Daotong hails from the healthcare sector, having successfully incubated early-stage startups and founded and managed publicly listed companies with market capitalizations exceeding RMB 10 billion. Committed to being not only a discoverer of value but also a creator of value, Daotong supports enterprise growth through comprehensive post-investment empowerment. The firm has repeatedly been honored among VCBeat’s TOP 100 Venture Capital Firms and TOP 20 Medical Device Investors, among other accolades.